211 related articles for article (PubMed ID: 30474722)
21. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
Lee YJ; Kim HS; Rim JH; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
BMC Cancer; 2020 Mar; 20(1):185. PubMed ID: 32131779
[TBL] [Abstract][Full Text] [Related]
22. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
23. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
[TBL] [Abstract][Full Text] [Related]
24. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
25. The BRCA1 c.788G > T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought.
De Paolis E; Pietragalla A; De Bonis M; Fagotti A; Urbani A; Scambia G; Minucci A
Mol Biol Rep; 2021 Mar; 48(3):2985-2992. PubMed ID: 33656647
[TBL] [Abstract][Full Text] [Related]
26. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment maximum standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic factor for ovarian clear cell carcinoma and low-grade serous carcinoma.
Matsuura T; Otsuka I; Ouchi T; Ouchi E; Asano R; Miyasaka N
Taiwan J Obstet Gynecol; 2021 Mar; 60(2):305-310. PubMed ID: 33678332
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
[TBL] [Abstract][Full Text] [Related]
30. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS
Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614
[TBL] [Abstract][Full Text] [Related]
32. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P
Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832
[TBL] [Abstract][Full Text] [Related]
33. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
Kim SR; Malcolmson J; Li X; Bernardini MQ; Hogen L; May T
Gynecol Oncol; 2021 Sep; 162(3):702-706. PubMed ID: 34256977
[TBL] [Abstract][Full Text] [Related]
34. Cell-stiffness and morphological architectural patterns in clinical samples of high grade serous ovarian cancers.
Azzalini E; Abdurakhmanova N; Parisse P; Bartoletti M; Canzonieri V; Stanta G; Casalis L; Bonin S
Nanomedicine; 2021 Oct; 37():102452. PubMed ID: 34311116
[TBL] [Abstract][Full Text] [Related]
35. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Reyes MC; Arnold AG; Kauff ND; Levine DA; Soslow RA
Mod Pathol; 2014 Oct; 27(10):1405-11. PubMed ID: 24577588
[TBL] [Abstract][Full Text] [Related]
36. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J
Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857
[TBL] [Abstract][Full Text] [Related]
37. CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Nougaret S; Lakhman Y; Molinari N; Feier D; Scelzo C; Vargas HA; Sosa RE; Hricak H; Soslow RA; Grisham RN; Sala E
AJR Am J Roentgenol; 2018 Apr; 210(4):918-926. PubMed ID: 29489407
[TBL] [Abstract][Full Text] [Related]
38. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
39. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
40. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
Vargas HA; Miccò M; Hong SI; Goldman DA; Dao F; Weigelt B; Soslow RA; Hricak H; Levine DA; Sala E
Radiology; 2015 Mar; 274(3):742-51. PubMed ID: 25383459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
